Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab vedotin alone or with pembrolizumab for urothelial cancer
2018-001527-39Phase 2Active
- Sponsor
- Seagen Inc.
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of enfortumab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (2 arms), sponsored by Seagen Inc. Primary endpoint: Objective response rate. Started Feb 2021; status: active.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2018-001527-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001527-39.